Jazz Pharmaceuticals Highlights Ziihera® Approval And Launch Plans
Jazz Pharmaceuticals hosts a Dec 11 webcast on Ziihera® (zanidatamab-hrii), the first dual HER2-targeted therapy for BTC.
Breaking News
Dec 05, 2024
Simantini Singh Deo
Image Source: https://www.google.com/imgres?q=Ziihera&imgurl=https%3A%2F%2Fjazzcares.com%2Fsites%2Fjazzcares%2Ffiles%2F2024-11%2Fprod-logo-ziihera_0.webp&imgrefurl=https%3A%2F%2Fjazzcares.com%2Fpatients%2Fziihera&docid=0rgoEFKUdfPczM&tbnid=usZuGA_PU7-JrM&vet=12ahUKEwji5Mr_h5CKAxUy_7sIHYavFugQM3oECGUQAA..i&w=495&h=175&hcb=2&ved=2ahUKEwji5Mr_h5CKAxUy_7sIHYavFugQM3oECGUQAA
Jazz Pharmaceuticals has announced a webcast scheduled for Wednesday, December 11, 2024, at 4:30 p.m. ET/9:30 p.m. GMT. The event will provide insights into the clinical data, patient needs, and commercialisation strategy for Ziihera® (zanidatamab-hrii). Ziihera® is the first chemotherapy-free dual HER2-targeted bispecific antibody approved for biliary tract cancer (BTC).
Ziihera received approval from the U.S. Food and Drug Administration (FDA) on November 20, 2024, for treating adults with HER2-positive (IHC 3+) BTC that is unresectable or metastatic and has been previously treated. The FDA approval is dependent upon HER2 status confirmation using an FDA-approved test.
The webcast will feature Jazz senior management outlining Ziihera’s commercial launch plans. Dr. Shubham Pant will discuss the BTC findings from the HERIZON-BTC-01 trial, which informed Ziihera’s clinical development and approval. Dr. Pant, MD., MBBS, is a professor at the University of Texas MD Anderson Cancer Centre.
